MedPage Today on MSN3d
Studies Hint at Potential Negative Effects of GLP-1 Drugs in Orthopedic Patients
SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
pharmaphorum1d
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
which was approved for SBS in adults in 2012 and children in 2019 – while AstraZeneca's GLP-1 drug Byetta/Bydureon (exenatide) has also been used off-label to treat the disorder. 9 Meters is ...
pharmaphorum4d
AstraZeneca improves diabetes pen to maintain its market share
The EC made its decision based on data from DURATION-NEO-1 clinical trial comparing Bydureon BCise and AZ'[s twice-daily exenatide formulation, Byetta. After 28 weeks of treatment, patients ...
Diabetes.co.uk5d
Retatrutide: How it Works, Evidence, Side Effects
Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...